In conclusion, endocrine therapy in combination with CDKi in patients with HR-positive/HER2-negative advanced breast cancer is a well-tolerated treatment, with manageable toxicity profile and low drug discontinuation rates. This evidence concerns the gene ERBB2 and breast cancer.